Hostname: page-component-7b7567c8c-9cwtv Total loading time: 0 Render date: 2026-11-19T10:41:08.485Z Has data issue: false hasContentIssue false

HbA1c Testing Before, During and After a Health System Crisis: A Public Sector Laboratory Analysis in the Western Cape, South Africa

Published online by Cambridge University Press:  19 November 2026

Elsie Kruger*
Affiliation:
Chemical Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, South AfricaNational Health Laboratory Services, Tygerberg Hospital , Cape Town, South Africa
Tonya Esterhuizen
Affiliation:
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa
Andre Kengne
Affiliation:
African Population and Health Research Center , Nairobi, KenyaNon-Communicable Disease Unit, South African Medical Research Council , Cape Town, South Africa
Rajiv Erasmus
Affiliation:
Chemical Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, South AfricaDepartment of Biochemical Sciences, Cape Faculty of Health and Wellness Sciences, Peninsula University of Technology , Cape Town, South AfricaCardiometabolic Health Research Unit, South African Medical Research Council , South Africa
Annalise Zemlin
Affiliation:
Chemical Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, South AfricaNational Health Laboratory Services, Tygerberg Hospital , Cape Town, South Africa
*
Corresponding author: Elsie Kruger; Email: eckruger@sun.ac.za
Rights & Permissions [Opens in a new window]

Abstract

Objective

Diabetes imposes a significant public health burden in South Africa, yet public sector glycated hemoglobin (HbA1c) testing patterns remain poorly characterized. This study examined HbA1c testing adherence and glycemic control in the Western Cape across the COVID-19 pandemic.

Methods

A retrospective observational study used National Health Laboratory Service data for adults in the Western Cape (January 2017-December 2022) across pre-pandemic, pandemic, and post-pandemic periods. A linear mixed-effects model, restricted to patients with a baseline HbA1c ≥7%, assessed associations between study period, facility location, testing interval, and HbA1c.

Results

After exclusions, 1,191,486 HbA1c measurements from 546,466 patients were included. Testing adherence was poor throughout, with 89.4% of pandemic-period tests and 88.7% of post-pandemic tests performed later than recommended. In patients with a baseline HbA1c ≥7% and at least two measurements, adjusted mean HbA1c increased from 9.6% pre-pandemic to 9.9% during the pandemic, then decreased to 9.7% post-pandemic (eight-month period), without returning to pre-pandemic levels. Non-metropolitan location was associated with higher HbA1c; testing interval length showed no meaningful association.

Conclusions

These findings suggest that the pandemic compounded pre-existing weaknesses in HbA1c monitoring rather than creating an entirely new problem. Continuous structural investments, including decentralized HbA1c testing and community-based monitoring, are needed to strengthen chronic disease care during future health-system disruptions.

Information

Type
Original Research
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc
Figure 0

Figure 1.Flow diagram showing selection of HbA1c measurements and patients included in the single measurement and longitudinal analyses.Figure 1 long description.

Figure 1

Table 1.Cohort characteristics and HbA1c testing patterns by study periodTable 1. long description.

Figure 2

Table 2.HbA1c testing interval adherence by HbA1c category and study periodTable 2. long description.

Figure 3

Figure 2.Adjusted mean HbA1c (%) by study period in patients with a baseline HbA1c ≥7% and repeated measurements. Points show estimated marginal means from a linear mixed-effects model (678,778 observations from 227,235 patients) adjusted for facility location (metropolitan or non-metropolitan), sequential test number, and testing interval, evaluated at mean covariate values. Error bars show 95% confidence intervals. Study periods: pre-pandemic, January 1, 2017 to March 25, 2020; pandemic, March 26, 2020 to April 5, 2022; post-pandemic, April 6 to December 31, 2022 (8 months).CI: Confidence intervals.

Figure 4

Table 3.Linear mixed-effects model: factors associated with HbA1c and adjusted mean HbA1c by study periodTable 3. long description.